Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 46, 4251s-4255s, August 1, 1986]
© 1986 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thorpe, S. M.
Right arrow Articles by Lonsdorfer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thorpe, S. M.
Right arrow Articles by Lonsdorfer, M.

Quantitative Immunological Detection of Estrogen Receptors in Nuclear Pellets from Human Breast Cancer Biopsies1

Susan M. Thorpe2, Anne E. Lykkesfeldt, Aase Vinterby and Michael Lonsdorfer

Department of Clinical Physiology, The Finsen Institute [S. M. T.], and Laboratory of Tumor Endocrinology, The Fibiger Institute [S. M. T., A. E. L., A. V.],3 Copenhagen, Denmark, and Abbott Laboratories, Frankfurt, Federal Republic of Germany [M. L.]

A rapid, convenient method for the quantitative determination of estrogen receptors (ER) under high salt (0.6 M KCI) conditions (such as in extracts of nuclear pellets from human breast cancer biopsies) using a commercially available kit [estrogen receptor enzyme immunoassay (ER-EIA) Monoclonal; Abbott] is described. This assay has been validated using breast tumor cytosol ER preparations. It determines total (both occupied and unoccupied) ER, it is insensitive to KCI at concentrations up to 0.8 M, and it can be used with ER preparations having very low protein concentrations. Results obtained using the ER-EIA method for breast tumor nuclear extracts have been compared to those obtained using the hydroxylapatite method, and higher values have been found using the ER-EIA method. The reasons for this discrepancy may be due to: (a) the sensitivity of ER binding to hydroxylapatite in high concentrations of KCI; (b) the temperature dependent degradation of the receptor complex at 30°C,the temperature commonly used to achieve exchange between radioactive estradiol and the endogenously bound estradiol; and (c) possible detection of immunoreactive, but non-ligand-binding forms of ER. The possibility that occurrence of "free" receptors in high salt extracts from nuclear pellets may be an artifact is discussed.

The availability of this ER-EIA suitable for nuclear ER determinations opens the possibility of extending correlations between the clinical course of breast cancer and the levels of the ER form (nuclear) that are thought to be of greatest physiological significance.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1986 by the American Association for Cancer Research.